Abstract
A hepatitis C virus (HCV) plasmid vaccine was constructed, based on class II-associated invariant chain peptide (CLIP) substitution which endogenously targets HCV non-structure protein 3 (NS3) CD4+ T helper 1(Th1) epitope (1248AA-1261AA) to major histocompatibility complex (MHC) class II antigen. The in vitro expression results demonstrated that the vaccine was expressed efficiently in COS-7 cell line. The expressed protein could co-localize in endo-membrane system with BALB/c mouse MHC class II molecule I-Ad. The recombinant invariant chain molecule could aggregate with BALB/c mouse I-Ad molecule and form the theoretical nonomer structure in the COS-7 cell line. The assembled molecules migrate to the cell surface by exocytosis. This has implications for HCV vaccine development.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
R Busch R Doebele NS Patil A Pashine ED Mellins (2000) ArticleTitleAccessory molecules of MHC class II peptide loading Curr. Opin. Immunol. 12 99–106 Occurrence Handle10679402 Occurrence Handle10.1016/S0952-7915(99)00057-6 Occurrence Handle1:CAS:528:DC%2BD3cXhsVOkurY%3D
ME Cramp S Rossol S Chokshi P Carucci R Williams NV Naoumov (2000) ArticleTitleHepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C Gastroenterology 118 346–355 Occurrence Handle10648463 Occurrence Handle10.1016/S0016-5085(00)70217-4 Occurrence Handle1:CAS:528:DC%2BD3cXpvF2ntA%3D%3D
HM Diepolder R Zachoval RM Hoffmann EA Wierenga T Santantonio MC Jung (1995) ArticleTitlePossible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection Lancet 346 1006–1007 Occurrence Handle7475549 Occurrence Handle10.1016/S0140-6736(95)91691-1 Occurrence Handle1:CAS:528:DyaK2MXpslSqsL0%3D
AE Esther Tienhoven Particlevan TB ten Brink J Bergen Particlevan F Koning W Eden Particlevan PM Broeren (2001) ArticleTitleInduction of antigen specific CD4+ T cell responses by invariant chain based vaccines Vaccine 19 1515–1519
S Fujii S Senju YZ Chen M Ando S Matsushita Y Nishimura (1998) ArticleTitleThe CLIP-substituted invariant chain efficiently targets an antigenic peptide to HLA class II pathway in L cells Hum. Immunol. 59 607–614 Occurrence Handle9757942 Occurrence Handle10.1016/S0198-8859(98)00058-5 Occurrence Handle1:CAS:528:DyaK1cXmtlenu7o%3D
JH Hoofnagle (1997) ArticleTitleHepatitis C: the clinical spectrum of disease Hepatology 26 15S–20S Occurrence Handle9305658 Occurrence Handle1:STN:280:ByiH2cbhvV0%3D
G Malcherek C Wirblich N Willcox HG Rammensee J Trowsdale A Melms (1998) ArticleTitleMHC class II-associated invariant chain peptide replacement by T cell epitopes: engineered invariant chain as a vehicle for directed and enhanced MHC class II antigen processing and presentation Eur. J. Immunol. 28 1524–1533 Occurrence Handle9603457 Occurrence Handle10.1002/(SICI)1521-4141(199805)28:05<1524::AID-IMMU1524>3.0.CO;2-T Occurrence Handle1:CAS:528:DyaK1cXjt1Gjur8%3D
JG McHutchison SC Gorden ER Schiff et al. (1998) ArticleTitleInterferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C New. Engl. J. Med. 339 1485–1492 Occurrence Handle9819446 Occurrence Handle10.1056/NEJM199811193392101 Occurrence Handle1:CAS:528:DyaK1cXnslGmtbs%3D
G Missale R Bertoni V Lamonaca A Valli M Massari C Mori MG Rumi M Houghton F Fiaccadori C Ferrari (1996) ArticleTitleDiffrent clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response J. Clin. Invest. 98 706–714 Occurrence Handle8698862 Occurrence Handle1:CAS:528:DyaK28XkvVeisrk%3D Occurrence Handle10.1172/JCI118842
T Nagata T Higashi T Aoshi M Suziki M Uchijima Y Koide (2002) ArticleTitleImmunization with plasmid DNA encoding MHC class II binding peptide/CLIP-replaced invariant chain(Ii) induces specific helper T cells in vivo: the assessment of Ii p31 and p41 isoforms as vehicles for immunization Vaccine 20 105–114
T Poynard P Marcellin SS Lee et al. (1998) ArticleTitleRandomised trial of interferon a2b plus ribavirin for 48 weeks or for 24 weeks versus interferon a2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus Lancet 352 1426–1432 Occurrence Handle9807989 Occurrence Handle10.1016/S0140-6736(98)07124-4 Occurrence Handle1:CAS:528:DyaK1cXnsVSmsLg%3D
A Sponaas C Carstens N Koch (1999) ArticleTitleC-terminal extension of the MHC class II-associated invariant chain by an antigenic sequence triggers activation of naive T cells Gene Ther. 6 1826–1834 Occurrence Handle10602378 Occurrence Handle10.1038/sj.gt.3301021 Occurrence Handle1:CAS:528:DyaK1MXnt1Kjtrc%3D
SL Tsai YF Liaw MH Chen CY Huang GC Kuo (1997) ArticleTitleDetection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity Hepatology 25 449–458 Occurrence Handle9021963 Occurrence Handle1:STN:280:ByiC2svit10%3D
J Bergen Particlevan SP Schoenberger F Verreck R Amons R Offringa F Koning (1997) ArticleTitleEfficient loading of HLA-DR with a T helper epitope by genetic exchange of CLIP Proc. Natl. Acad. Sci. USA 94 7499–7502 Occurrence Handle9207120
ZX Zhang DR Milich DL Peterson A Birkett R Schvarcz O Weiland M Sallberg (1997b) ArticleTitleInterferon-alpha treatment induces delayed CD4 proliferative responses to the hepatitis C virus nonstructural protein 3 regardless of the outcome of therapy J. Infect. Dis. 175 1294–1301 Occurrence Handle1:CAS:528:DyaK2sXjslynu7Y%3D Occurrence Handle10.1086/513972
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gao, M., Wang, HP., Wang, YN. et al. Target HCV NS3 CD4+ Th1 Epitope to Major Histocompatibility Complex Class II Pathway. Biotechnol Lett 28, 3–8 (2006). https://doi.org/10.1007/s10529-005-4679-0
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10529-005-4679-0